London: Thursday, March 31, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at March 31, 2016, the issued share capital of Chi-Med consisted of 60,283,118 ordinary shares of US$1.00 each, with each share carrying one right to vote and with no shares held in treasury.
The above figure of 60,283,118 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the Financial Conduct Authority’s Disclosure Rules and Transparency Rules.
Ends
Chi-Med
Christian Hogg, CEO
+852 2121 8200
International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson
+44 7973 611 888 (Mobile)
U.S. Based Media Enquiries
Brad Miles, BMC Communications
+1 (917) 570 7340
Susan Duffy, BMC Communications
+1 (917) 499 8887
Investor Relations
Jillian Connell, The Trout Group
+1 (646) 378 2956
David Dible, Citigate Dewe Rogerson
+44 20 7638 9571
+44 7967 566 919 (Mobile)
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts
+44 20 7886 2500
Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.